SCHEMBL150529

SCHEMBL150529

CC(C)(C)C(OC(N)=O)c1oc2ccccc2c(=O)c1-c1ccccc1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NMUR2 Q9GZQ4 4/20 0.44
HPGD P15428 2/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NTRK1 P04629 1/20 0.39
PLK3 Q9H4B4 1/20 0.39
KMT2A Q03164 4/20 0.37
HSD17B10 Q99714 3/20 0.37
MEN1 O00255 2/20 0.37
KDM4E B2RXH2 2/20 0.37
CYP3A4 P08684 2/20 0.37
ALDH1A1 P00352 1/20 0.37
PDE5A O76074 1/20 0.36
CYP2C9 P11712 1/20 0.35
TSHR P16473 1/20 0.35
CYP2C19 P33261 1/20 0.35
CA1 P00915 3/20 0.35
CA2 P00918 3/20 0.35
ALOX5 P09917 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9587 0.74 NMUR2 (0.51) NMUR2HPGDNPC1RAB9ASMN1; SMN2
SCHEMBL9226 0.71 NMUR2 (0.48) NMUR2HPGDNPC1RAB9ASMN1; SMN2
SCHEMBL9340 0.70 NMUR2 (0.57) NMUR2HPGDNPC1RAB9ASMN1; SMN2
SCHEMBL8587 0.69 NMUR2 (0.45) NMUR2HPGDNPC1RAB9ASMN1; SMN2
SCHEMBL12095235 0.68 KDM4E (0.50) NMUR2HPGDNPC1RAB9ASMN1; SMN2
SCHEMBL12095236 0.68 NMUR2 (0.49) NMUR2HPGDNPC1RAB9ASMN1; SMN2
SCHEMBL22275953 0.67 NMUR2 (0.44) NMUR2HPGDNPC1RAB9ASMN1; SMN2
SCHEMBL27900112 0.67 NMUR2 (0.51) NMUR2HPGDNPC1RAB9ASMN1; SMN2
SCHEMBL9471 0.67 NMUR2 (0.54) NMUR2HPGDNPC1RAB9ASMN1; SMN2
SCHEMBL8732 0.67 NMUR2 (0.54) NMUR2HPGDNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 US claimed
US-10442783-B2 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2019-10-15 US disclosed
US-9018375-B2 Substituted chromenes as kinase modulators RHIZEN PHARMACEUTICALS SA (CH) 2015-04-28 US disclosed
US-20140080827-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2014-03-20 US disclosed
US-8642607-B2 4H-chromen-4-one compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2014-02-04 US disclosed
US-20120059001-A1 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2012-03-08 US disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10442783-B2 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases PIK3CB, PIK3CD, PDPK1 NMUR2 4454/4885HPGD 2895/4885NPC1 1387/4885
US-20140080827-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB NMUR2 4228/4885HPGD 2910/4885NPC1 1419/4885
US-20110118257-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB NMUR2 4228/4885HPGD 2910/4885NPC1 1419/4885
US-20120059001-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB NMUR2 4228/4885HPGD 2910/4885NPC1 1419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.